



# Pear Bio

Ending the progression of cancer

<b>Area</b>	Diagnostics & Treatment
<b>Headquarter</b>	London, UK
<b>Countries of operation</b>	UK, US
<b>Founding year</b>	2017
<b>Status</b>	Pilot


<b>Incubator</b>	RebelBio
<b>Awards</b>	N/A
<b>Patents</b>	US 10413567 US 10548919 FDA
<b>Revenue (last yr)</b>	£50k
<b>Funds raised</b>	\$380k
<b>Currently raising:</b>	\$3M

## Summary

Pear Bio uses organ-on-a-chip and computer vision technology to recreate visualize and compute tumour microenvironment-driven mechanisms of cancer spread and drug resistance. This allows us to compare drug performance side-by-side on patient tumour samples and eliminate ineffective treatment options before patients get them.

## USE OF FUNDS

■ Product Dev ■ Staff ■ Clinical studies ■ R&D



## Interested? Get in touch

✉ [greg@clab.ventures](mailto:greg@clab.ventures)  
[www.pearbio.com](http://www.pearbio.com)

